We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Mediclinic International owns and operates hospitals and medical facilities. The H...
Mediclinic International owns and operates hosp...
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is ap...
Lexicon Pharmaceuticals is a fully integrated b...
Ocugen is a clinical stage biopharmaceutical company focused on discovering, devel...
Ocugen is a clinical stage biopharmaceutical co...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.